Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352

Diabetes Care. 2021 Aug;44(8):e165-e166. doi: 10.2337/dc21-0904. Epub 2021 Jul 20.

Authors

Dinah Foer¹, Katherine N Cahill²

Affiliations

¹ Division of Allergy and Clinical Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA dfoer@bwh.harvard.edu.
² Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Disease Progression
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / therapeutic use

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Glucagon-Like Peptide 1

Grants and funding

K23 AI118804/AI/NIAID NIH HHS/United States